Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | GPR3 | P46089 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TERT | O14746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16420314 | 0.92 | KDM4E (0.35) | KDM4EALDH1A1GAAHPGDALOX12 | |
| SCHEMBL17131424 | 0.92 | KDM4E (0.35) | KDM4EALDH1A1GAAHPGDALOX12 | |
| SCHEMBL24596461 | 0.91 | KDM4E (0.37) | KDM4EALDH1A1GAAHPGDALOX12 | |
| SCHEMBL16420322 | 0.89 | KDM4E (0.47) | KDM4EALDH1A1GAAHPGDALOX12 | |
| SCHEMBL16420354 | 0.85 | PTPN2 (0.31) | KDM4EALDH1A1GAAHPGDALOX12 | |
| SCHEMBL16424290 | 0.85 | KDM4E (0.31) | KDM4EALDH1A1GAAHPGDALOX12 | |
| SCHEMBL16709188 | 0.84 | HSD17B10 (0.39) | KDM4EALDH1A1GAAHPGDALOX12 | |
| SCHEMBL16420349 | 0.84 | KDM4E (0.41) | KDM4EALDH1A1GAAHPGDALOX12 | |
| SCHEMBL17655184 | 0.84 | HSD17B10 (0.39) | KDM4EALDH1A1GAAHPGDALOX12 | |
| SCHEMBL16769708 | 0.82 | ALDH1A1 (0.42) | KDM4EALDH1A1GAAHPGDALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10930866-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2021-02-23 | — | — | US | disclosed |
| US-20200176694-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2020-06-04 | — | — | US | disclosed |
| US-20170250354-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2017-08-31 | — | — | US | disclosed |
| US-9748504-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| US-20150280146-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2015-10-01 | — | — | US | disclosed |
| US-20150028290-A1 | HETEROLEPTIC OSMIUM COMPLEX AND METHOD OF MAKING THE SAME | UNIVERSAL DISPLAY CORPORATION (US) | 2015-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10930866-B2 | Organic electroluminescent materials and devices | OSBPL3, OR10J3, OSBP2 | KDM4E 3560/4885ALDH1A1 1215/4885GAA 4541/4885 |
| US-20150280146-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OXER1, SSB, RO60 | KDM4E 2698/4885ALDH1A1 2401/4885GAA 3572/4885 |
| US-20200176694-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OSBPL3, OR10J3, OSBP2 | KDM4E 3560/4885ALDH1A1 1215/4885GAA 4541/4885 |
| US-20170250354-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OSBPL3, OR10J3, OSBP2 | KDM4E 3560/4885ALDH1A1 1215/4885GAA 4541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.